Evotec allies with Odyssey

Evotec has entered a strategic R&D collaboration with autoimmune and inflammatory diseases biotech Odyssey Therapeutics. Odyssey will use Evotec’s integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. 

“By combining high-throughput experimentation with machine learning-driven analysis, the collaboration is designed to accelerate the identification of validated hit series and enable the rapid progression of promising therapeutic programmes,” Evotec stated. “By bringing together complementary scientific and technological strengths, the companies aim to accelerate early-stage research and efficiently generate and advance new medicines.”

Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, aligning value creation with successful discovery outcomes. No other financial details were disclosed.